|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Lower serum BChE levels were associated with lower BMI (p < 0.001), advanced tumor stage (p = 0.04), poor treatment response (p = 0.002), the occurrence of disease recurrence (p = 0.003), and the risk of death (p < 0.001).
|
30737542 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
In multivariate analysis, BChE levels were most significantly associated with OS, whereas BChE level and tumor grade were significantly associated with DFS.
|
29177431 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The random-survival-forest analysis identified baseline cholinesterase and bilirubin as the most important variables (forest-averaged lowest minimal depth, 1.2 and 1.5, respectively), followed by the type of primary tumor (1.7), age (2.4), tumor burden (2.8), and presence of extrahepatic disease (3.5).
|
29146692 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The evident response to treatment indicates that plasma butyrylcholinesterase is a good biomarker of tumor response to therapy.
|
28375942 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Ascites, cholinesterase, c-reactive and alpha-feto protein and tumor size were identified as prognostic factors.
|
27598949 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
EGFR (4/10 tumors), BCHE (3/10), and TP53 (2/10) were identified recurrently with validated tumor-specific non-synonymous mutations; and the remaining mutations were specific to individual tumors.
|
24449147 |
2014 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Tumor size was significantly higher when the ACHE gene was amplified, and the total number of alterations (amplifications plus deletions) of the BCHE gene was positively correlated with tumor malignancy grade.
|
20193849 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation.
|
20708154 |
2010 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The binding of AChE and BuChE with antibodies was unaffected by the neoplasia.
|
12000217 |
2002 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The genes which were selected for their known function and their potential involvement in tumour development included the genes for ribosomal protein L22 (RPL22), butyrylcholinesterase (BCHE), glucose transporter 2 (SLC2A2), transferrin receptor (TFRC), thrombopoietin (THPO) and the phosphatidylinositol-3 kinase catalytic alpha polypeptide (PIK3CA).
|
10492640 |
1999 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The frequent coamplification in ovarian carcinomas of ACHE and CHE genes implicates cholinesterases in neoplastic growth and/or proliferation.
|
2394839 |
1990 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
HPO |
|
|
|